UPDATE: Deutsche Bank Raines PT to $45 on Medtronic Following Top-Line Beat
Deutsche Bank reiterated its Hold rating on Medtronic (NYSE: MDT) but increased its price target from $43 to $45.
Deutsche Bank noted, "Top line beats, but EPS in line; Maintain Hold. In F2Q13, Medtronic's sales grew 5% ex-FX driven by the successful launch and share gains in the drug-eluting stent business (which accounted for 1.6%-pts of growth). While sales were better, EPS was in-line with Consensus ($0.01 below our estimate) due mainly to lower gross margins. Medtronic managed the P&L noting it took one-time gains from selling treasuries and minority investments to help offset FX hedging losses. We maintain our Hold rating but we are slightly increasing our PT to $45 from $43 given the more stable top line performance in the quarter and expectations going forward."
Medtronic closed at $42.75 on Wednesday.
Latest Ratings for MDT
|Mar 2015||BMO Capital||Maintains||Outperform|
|Dec 2014||Bank of America||Maintains||Buy|
© 2015 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.